Article
Oncology
James M. Foran, Zhuoxin Sun, Catherine Lai, Hugo F. Fernandez, Larry D. Cripe, Rhett P. Ketterling, Janis Racevskis, Selina M. Luger, Elisabeth Paietta, Hillard M. Lazarus, Yanming Zhang, John M. Bennett, Ross L. Levine, Jacob M. Rowe, Mark R. Litzow, Martin S. Tallman
Summary: This study examined the association of obesity with AML and its impact on clinical outcomes. The results showed that obesity was associated with certain clinical and genetic features of AML, but did not affect patient survival.
Article
Hematology
Tapan M. Kadia, Farhad Ravandi, Gautam Borthakur, Marina Konopleva, Courtney D. DiNardo, Naval Daver, Naveen Pemmaraju, Rashmi Kanagal-Shamanna, Xuemei Wang, Xuelin Huang, Sherry Pierce, Caitlin Rausch, Jan Burger, Alessandra Ferrajoli, Nitin Jain, Uday Popat, Zeev Estrov, Srdan Verstovsek, Elias Jabbour, Guillermo Garcia-Manero, Hagop Kantarjian
Summary: The study evaluated two new lower-intensity regimens for older patients with newly diagnosed AML, showing high response rates and overall survival outcomes.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Hematology
Yue-ying Mao, Hua-cong Cai, Kai-ni Shen, Long Chang, Lu Zhang, Yan Zhang, Jun Feng, Wei Wang, Chen Yang, Tie-nan Zhu, Ming-hui Duan, Dao-bin Zhou, Xin-xin Cao, Jian Li
Summary: This study found that for younger and fit patients with newly diagnosed AML, idarubicin 14 mg/m(2) plus cytarabine was a safe and effective intensive regimen, with a high rate of complete remission achieved after one course of induction therapy.
ANNALS OF HEMATOLOGY
(2022)
Article
Cell Biology
Xuan Chu, Liang Zhong, Wenran Dan, Xiao Wang, Zhonghui Zhang, Zhenyan Liu, Yang Lu, Xin Shao, Ziwei Zhou, Shuyu Chen, Beizhong Liu
Summary: This study found that AML cells with DNMT3A R882H mutation exhibited high proliferative and anti-apoptotic activities, as well as resistance to daunorubicin treatment. The NRF2 pathway played an important role in the regulation of cell apoptosis, and the expression of NRF2 was regulated by DNMT3A R882H mutation through protein stability rather than methylation. Targeting NRF2 might be a potential therapeutic strategy for AML patients with DNMT3A R882H mutation.
CELL COMMUNICATION AND SIGNALING
(2022)
Article
Hematology
Tapan M. Kadia, Farhad Ravandi, Matteo Molica, Alex Bataller, Gautam Borthakur, Naval Daver, Elias Jabbour, Courtney D. Dinardo, Naveen Pemmaraju, Nitin Jain, Alessandra Ferrajoli, Musa Ylimaz, Prithviraj Bose, Rebecca Slack Tidwell, Kayleigh R. Marx, Caitlin R. Rausch, Rashmi Kanagal-Shamanna, Sa Wang, Rabiul Islam, Richard Champlin, Elizabeth Shpall, Marina Konopleva, Guillermo Garcia-Manero, Hagop Kantarjian
Summary: The addition of cladribine or sorafenib to standard chemotherapy has improved survival in patients with newly-diagnosed acute myeloid leukemia (AML). The combination of cladribine, idarubicin, and intermediate-dose cytarabine (CLIA) showed high rates of complete remission in AML patients, with even better results when sorafenib was added in patients with FLT3-ITD mutated AML.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Emeline Bollaert, Melissa Claus, Virginie Vandewalle, Sandrine Lenglez, Ahmed Essaghir, Jean-Baptiste Demoulin, Violaine Havelange
Summary: The study found that miR-15a-5p induces chemoresistance in AML cells by inhibiting daunorubicin-induced autophagy, suggesting that this miRNA could be a promising therapeutic target for chemoresistant AML patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Hematology
Tapan M. Kadia, Patrick K. Reville, Gautam Borthakur, Musa Yilmaz, Steven Kornblau, Yesid Alvarado, Courtney D. Dinardo, Naval Daver, Nitin Jain, Naveen Pemmaraju, Nicholas Short, Sa A. Wang, Rebecca S. S. Tidwell, Rabiul Islam, Marina Konopleva, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian
Summary: The addition of venetoclax to intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome was found to be safe and effective, leading to high rates of durable MRD-negative remissions and favorable event-free survival and overall survival outcomes.
LANCET HAEMATOLOGY
(2021)
Article
Hematology
Jorge Sierra, Pau Montesinos, Xavier Thomas, Laimonas Griskevicius, Thomas Cluzeau, Denis Caillot, Ollivier Legrand, Clara Minotti, Mario Luppi, Firas Farkas, Bourras-Rezki Bengoudifa, Geralyn Gilotti, Sejla Hodzic, Alessandro Rambaldi, Adriano Venditti
Summary: The pivotal RATIFY study demonstrated that midostaurin combined with standard chemotherapy significantly reduced mortality in adult patients with newly diagnosed FLT3(mut) acute myeloid leukemia. This open-label, multicenter phase 3b trial aimed to further assess the safety and efficacy of midostaurin plus chemotherapy in different age groups. The results showed that the safety and efficacy of midostaurin remained consistent with previous findings regardless of age, sex, or induction regimen.
Article
Oncology
Yong Zhuang, Kefei Wu, Xiaofan Zhu, Jiaoyang Cai, Shaoyan Hu, Ju Gao, Hua Jiang, Xiaowen Zhai, Xin Tian, Yongjun Fang, Runming Jin, Qun Hu, Hui Jiang, Ningling Wang, Lirong Sun, Wing Kwan Leung, Minghua Yang, Kaili Pan, Xuedong Wu, Changda Liang, Shuhong Shen, Jie Yu, Xiuli Ju
Summary: This study aimed to determine the feasibility of reducing the dosage of daunorubicin during the remission-induction phase for specific types of low-risk ALL patients. The results showed that only B-lineage ALL patients meeting specific criteria were suitable candidates for dosage reduction of daunorubicin.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Li Ye, Lingsu Gao, Qiansong Cheng, Feng Guo, Liang He, Tingting Yuan, Ming Zhu, Yuanfang Ma, Min Pan, Xiandeng Chu, Meiqi Ding, Guohui Yu
Summary: The study found that AML patients receiving single-intermediate dose cytarabine after reaching CR showed better relapse-free time and similar toxic effects compared to those receiving standard-dose cytarabine, indicating that ID cytarabine can improve the prognosis of AML patients.
Review
Oncology
Aseel Alsouqi, Emily Geramita, Annie Im, Gertjan Kaspers, Kapil Saxena
Summary: This review article discusses the treatment options and challenges for older and medically unfit AML patients, including historical practices, current standard treatments, and future therapeutic options in clinical trials.
Article
Cell Biology
Jing-Ting Chiou, Nan-Chieh Huang, Chia-Hui Huang, Liang-Jun Wang, Yuan-Chin Lee, Yi-Jun Shi, Long-Sen Chang
Summary: This study elucidates the pathway of DNR-induced cell death in acute myeloid leukemia (AML) cells, primarily through upregulation of NOXA leading to the degradation of MCL1 and BCL2L1. Furthermore, the NOX4-ROS-p38 MAPK-GSK3β-CREB axis plays a crucial role in this process.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Han-lin Wang, Jia-nan Li, Wei-juan Kan, Gao-ya Xu, Guang-hao Luo, Ning Song, Wen-biao Wu, Bo Feng, Jing-feng Fu, Yu-tong Tu, Min-min Liu, Ran Xu, Yu-bo Zhou, Gang Wei, Jia Li
Summary: Current therapy for acute myeloid leukemia (AML) is obstructed by drug resistance. This study identified autophagy activation as a potential target and found that inhibiting autophagy could enhance AML cell sensitivity to chemotherapy drugs. The combination therapy of chloroquine phosphate and chemotherapy drugs showed a synergistic antitumor effect in vitro and in vivo.
ACTA PHARMACOLOGICA SINICA
(2023)
Review
Oncology
Irene Urbino, Carolina Secreto, Matteo Olivi, Vincenzo Apolito, Stefano D'Ardia, Chiara Frairia, Valentina Giai, Semra Aydin, Roberto Freilone, Chiara Dellacasa, Luisa Giaccone, Dario Ferrero, Ernesta Audisio, Alessandro Busca, Marco Cerrano
Summary: The treatment paradigm for older AML patients is becoming increasingly challenging due to the evolving criteria for eligibility, introduction of new agents, implications of precision medicine, and emphasis on quality of life and supportive care. This complex and heterogeneous population is now able to access a wider range of therapeutic options, but managing these options effectively requires careful consideration of each patient's individual characteristics.
Review
Oncology
David C. de Leeuw, Gert J. Ossenkoppele, Jeroen J. W. M. Janssen
Summary: The treatment of elderly patients with acute myeloid leukemia is a challenge due to patient diversity and disease heterogeneity. Determining fitness and selecting appropriate treatments based on factors like age, performance status, and comorbidities is important. Recent developments such as the addition of venetoclax, targeted therapy with IDH1/2 and FLT3 inhibitors, and improved formulations of existing drugs have improved treatment outcomes. Selecting patient-tailored treatments based on fitness and disease biology is essential.
CURRENT ONCOLOGY REPORTS
(2022)
Article
Hematology
Stephane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Joerg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Doehner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo
Summary: This study compared the efficacy of the oral IDH2 inhibitor enasidenib with conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 AML. Enasidenib significantly improved event-free survival, time to treatment failure, overall response rate, hematologic improvement, and transfusion independence compared to CCR. However, there was no significant difference in overall survival, possibly due to early dropout and subsequent AML-directed therapies.
Letter
Oncology
Loic Vasseur, Remi Favier, Rathana Kim, Florence Rabian, Aurelie Cabannes-Hamy, Bruno Cassinat, Nabih Maslah, Nadia Vasquez, Emmanuelle Clappier, Jean-Jacques Kiladjian, Nicolas Boissel
PEDIATRIC BLOOD & CANCER
(2023)
Article
Biophysics
Paul Chauvet, Annalisa Paviglianiti, Myriam Labopin, Helene Labussiere, Nicolas Boissel, Marie Robin, Natacha Maillard, Marie Ouachee-Chardin, Edouard Forcade, Xavier Poire, Sylvain Chantepie, Anne Huynh, Claude Eric Bulabois, Mathieu Leclerc, Sebastien Maury, Patrice Chevallier, Thomas Cluzeau, Jean-Baptiste Mear, Jerome Cornillon, Karin Bilger, Celestine Simand, Yves Beguin, Marie-Therese Rubio, Ibrahim Yakoub-Agha, Eolia Brissot
Summary: This study compared the efficacy and safety of blinatumomab with donor lymphocyte infusion (DLI) versus blinatumomab alone in relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell transplantation (allo-HCT). The results showed that adding DLI to blinatumomab treatment did not improve outcomes in B-ALL patients who relapsed after allo-HCT.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Hematology
Laure Goursaud, Celine Berthon, Bruno Quesnel
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Nicolas Boissel, Sabina Chiaretti, Cristina Papayannidis, Josep-Maria Ribera, Renato Bassan, Andrey N. Sokolov, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Gerhard Zugmaier, Robin Foa, Alessandro Rambaldi
Summary: This retrospective study included adult patients with B-cell ALL who were treated with blinatumomab for MRD+ or R/R B-cell ALL. The results showed significant treatment responses and survival benefits in both groups of patients.
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Stephane de Botton, Thomas Cluzeau, Carlos Vigil, Rachel J. Cook, Philippe Rousselot, David A. Rizzieri, Jane L. Liesveld, Pierre Fenaux, Thorsten Braun, Anne Banos, Joseph G. Jurcic, Mikkael A. Sekeres, Michael R. Savona, Gail J. Roboz, Dale Bixby, Kate Madigan, Angela Volkert, Kristin Stephens, Qing Kang-Fortner, Kristen Baker, Sofia Paul, Michael McKeown, John Carulli, Matthew Eaton, Graeme Hodgson, Christopher Fiore, Michael J. Kelly, David A. Roth, Eytan M. Stein
Summary: A superenhancer at the RARA gene is associated with RARA mRNA overexpression in certain types of leukemia. Tamibarotene, an oral RAR alpha agonist, showed effectiveness in preclinical AML models with RARA overexpression. In a clinical study, the combination of tamibarotene and azacitidine demonstrated high response rates in RARA-positive AML patients.
Article
Hematology
Stephane de Botton, Pierre Fenaux, Karen Yee, Christian Recher, Andrew H. Wei, Pau Montesinos, David C. Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Montserrat Arnan, William Blum, Daniela Cilloni, Devendra K. Hiwase, Joseph G. Jurcic, Juergen Krauter, Xavier Thomas, Justin M. Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jorge Cortes
Summary: Olutasidenib (FT-2102) is an effective and selective oral inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). In a pivotal cohort study, olutasidenib monotherapy showed a complete remission (CR) plus CR with partial hematologic recovery (CRh) rate of 35% and an overall response rate of 48% in IDH1 inhibitor-naive patients with mIDH1R132 relapsed/refractory acute myeloid leukemia (AML). The median duration of CR/CRh was 25.9 months, and the median overall survival was 11.6 months. Grade 3 or 4 adverse events included febrile neutropenia, anemia, thrombocytopenia, and neutropenia. Differentiation syndrome adverse events occurred in 14% of patients, with one fatal case reported. Olutasidenib provides a therapeutic advance in this poor-prognostic population of AML patients with mIDH1 R/R. This trial was registered at www.clinicaltrials.gov as #NCT02719574.
Letter
Hematology
Courtney D. DiNardo, Stephane De Botton, Daniel A. Pollyea, Richard M. Stone, Jessica K. Altman, Amir T. Fathi, Tharin Limsakun, Min Liang, Sung Choe, Mohammad Hossain, Adriana E. Tron, Qian Meng, Stephanie M. Kapsalis, Shuchi S. Pandya, Eytan M. Stein
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Marco Cerrano, Sylvie Chevret, Emmanuel Raffoux, Florence Rabian, Marie Sebert, Sandrine Valade, Raphael Itzykson, Virginie Lemiale, Lionel Ades, Nicolas Boissel, Herve Dombret, Elie Azoulay, Etienne Lengline
Summary: A study found that a short course of intravenous dexamethasone can reduce early mortality and improve overall survival in patients with hyperleukocytic acute myeloid leukemia (AML). The results of this study suggest that dexamethasone administration can be a promising strategy for treating high white blood cell AML.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Lucien Courtois, Aurelie Cabannes-Hamy, Rathana Kim, Marine Delecourt, Antoine Pinton, Guillaume Charbonnier, Melanie Feroul, Charlotte Smith, Giulia Tueur, Cecile Pivert, Estelle Balducci, Mathieu Simonin, Laure Helene Angel, Salvatore Spicuglia, Nicolas Boissel, Guillaume P. Andrieu, Vahid Asnafi, Philippe Rousselot, Ludovic Lhermitte
Summary: T-cell acute lymphoblastic leukemia (T-ALL) is a hematological malignancy with a poor prognosis, and IL-7R expression can be used as a biomarker for predicting sensitivity to JAK inhibitors.
Letter
Hematology
C. Rouzaud, L. Vercellino, E. De Kerviler, E. Raffoux, M. Balsat, A. Marcais, M. -E. Dourthe, V. Meignin, V. Asnafi, E. MacIntyre, N. Boissel, E. Lengline
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Loic Vasseur, Laurene Fenwarth, Jerome Lambert, Stephane de Botton, Martin Figeac, Celine Villenet, Mael Heiblig, Pierre-Yves Dumas, Christian Recher, Celine Berthon, Emilie Lemasle, Delphine Lebon, Juliette Lambert, Christine Terre, Karine Celli-Lebras, Herve Dombret, Claude Preudhomme, Meyling Cheok, Raphael Itzykson, Nicolas Duployez
Summary: The expression of LSC17 gene is associated with risk stratification and measurable residual disease in AML patients, and high LSC17 expression is related to poor treatment response and shorter survival.
Letter
Hematology
Jerome Lambert, Roberta Di Blasi, Florence Rabian, Marie-Emilie Dourthe, Andre Baruchel, Catherine Thieblemont, Nicolas Boissel, Vincent Levy, Marie-Quitterie Picat, Sylvie Chevret
Letter
Hematology
Marie Emilie Dourthe, Lucien Courtois, Guillaume P. Andrieu, Mathieu Simonin, Aurore Touzart, Ludovic Lhermitte, Arnaud Petit, Nicolas Boissel, Andre Baruchel, Vahid Asnafi, Elizabeth Macintyre
Article
Oncology
Rathana Kim, Hugo Bergugnat, Lise Larcher, Matthieu Duchmann, Marie Passet, Stephanie Gachet, Wendy Cuccuini, Marina Lafage-Pochitaloff, Cedric Pastoret, Nathalie Grardel, Vahid Asnafi, Beat W. Schaefer, Eric Delabesse, Raphael Itzykson, Lionel Ades, Yosr Hicheri, Yves Chalandon, Carlos Graux, Patrice Chevallier, Mathilde Hunault, Thibaut Leguay, Francoise Huguet, Veronique Lheritier, Herve Dombret, Jean Soulier, Philippe Rousselot, Nicolas Boissel, Emmanuelle Clappier
Summary: Low hypodiploidy is a common subtype of B-cell acute lymphoblastic leukemia (B-ALL) in older adults, characterized by somatic TP53 biallelic alteration. The study reveals a link between aging and low hypodiploidy ALL, with TP53-mutant clonal hematopoiesis serving as a preleukemic reservoir that can give rise to aneuploidy and B-ALL.
BLOOD CANCER DISCOVERY
(2023)